Search This Blog

Monday, April 27, 2026

Jazz Priority Review for Ziihera® (zanidatamab-hrii) Combinations in gastric cancers

 Prescription Drug User Fee Act (PDUFA) date set for August 25, 2026

https://www.prnewswire.com/news-releases/jazz-pharmaceuticals-announces-fda-acceptance-and-priority-review-of-supplemental-biologics-license-application-for-ziihera-zanidatamab-hrii-combinations-in-first-line-her2-locally-advanced-or-metastatic-gea-302753741.html

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.